Published in Blood on May 15, 1998
S100A4 regulates macrophage chemotaxis. Mol Biol Cell (2010) 1.19
Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology. World J Gastroenterol (2001) 0.90
Regulation of tyrosine phosphorylation in macrophage phagocytosis and chemotaxis. Arch Biochem Biophys (2011) 0.86
Separation and characterization of the activated pool of colony-stimulating factor 1 receptor forming distinct multimeric complexes with signalling molecules in macrophages. Mol Cell Biol (1999) 0.81
Differential expression of FAK and Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines. Clin Exp Metastasis (2011) 0.81
A role for the protein tyrosine phosphatase CD45 in macrophage adhesion through the regulation of paxillin degradation. PLoS One (2013) 0.78
The nonreceptor protein tyrosine kinase Pyk2 promotes the turnover of monocytes at steady state. J Leukoc Biol (2017) 0.75
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science (1985) 7.70
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Human T lymphotropic virus type III infection of human alveolar macrophages. Blood (1986) 3.66
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
The acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.49
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med (1989) 2.95
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
RAFTK/Pyk2-mediated cellular signalling. Cell Signal (2000) 2.76
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med (1987) 2.31
Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med (1985) 2.20
Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem (1995) 2.17
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature (1987) 1.91
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med (1990) 1.89
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann Intern Med (1986) 1.88
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol (1987) 1.83
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 1.78
The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1-integrin stimulation in B cells and binds to p130cas. J Biol Chem (1997) 1.69
Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses (1987) 1.65
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest (1989) 1.61
The histiocytic disorders: a pathophysiologic analysis. Ann Intern Med (1981) 1.50
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem (2000) 1.46
Immune (gamma) interferon produced by a human T-lymphoblast cell line. Nature (1981) 1.45
Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. J Infect Dis (1992) 1.44
Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol (1991) 1.41
HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood (2001) 1.40
Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J Virol (1989) 1.38
Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes. Blood (1996) 1.38
Behavioral risk factors for HIV infection among homosexual men at a Boston community health center. Am J Public Health (1988) 1.37
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem (1996) 1.37
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene (2009) 1.35
Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol (1999) 1.34
Hematologic manifestations of the human immune deficiency virus (HIV). Semin Hematol (1988) 1.34
HTLV-III infection among health care workers. Association with needle-stick injuries. JAMA (1985) 1.31
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem (2000) 1.31
The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood (1998) 1.30
A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties. Proc Natl Acad Sci U S A (1991) 1.28
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol (1998) 1.28
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells. J Virol (1990) 1.28
Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood (1994) 1.26
Epidemic of the acquired immunodeficiency syndrome: a need for economic and social planning. Ann Intern Med (1983) 1.24
Characterization of Mayven, a novel actin-binding protein predominantly expressed in brain. Mol Biol Cell (1999) 1.23
Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection. J Clin Microbiol (1986) 1.22
Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. Biol Psychiatry (1997) 1.21
Pathophysiology and management of HIV-associated hematologic disorders. Blood (1989) 1.20
RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene (2000) 1.20
Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem (1999) 1.20
CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells. J Virol (1990) 1.20
NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation. J Cell Biol (1998) 1.18
Stromal cell-derived factor-1 alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. J Immunol (1998) 1.18
Pathogenesis of B cell lymphoma in a patient with AIDS. Blood (1986) 1.18
Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol (1987) 1.18
Antibodies to human T-lymphotropic virus type III (HTLV-III) in saliva of acquired immunodeficiency syndrome (AIDS) patients and in persons at risk for AIDS. Blood (1986) 1.17
Immunogenic nature of a Pol gene product of HTLV-III/LAV. Blood (1987) 1.17
Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem (2000) 1.15
HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood (2000) 1.12
Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). J Infect Dis (1990) 1.11
Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood (1992) 1.11
The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1. J Biol Chem (1997) 1.11
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Stromal cell-derived factor 1 alpha-induced chemotaxis in T cells is mediated by nitric oxide signaling pathways. J Immunol (2001) 1.09
The tyrosine kinase PYK-2/RAFTK regulates natural killer (NK) cell cytotoxic response, and is translocated and activated upon specific target cell recognition and killing. J Cell Biol (2000) 1.09
Slit: a roadblock for chemotaxis. Sci STKE (2001) 1.08
Activation of P2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. J Biol Chem (1998) 1.08
Histopathology of the inferior turbinate with compensatory hypertrophy in patients with deviated nasal septum. Laryngoscope (2000) 1.07
Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. Blood (1985) 1.07
Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem (1994) 1.06
Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood (1990) 1.05
Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells. J Biol Chem (1988) 1.05
Tyrosine phosphorylation of the related adhesion focal tyrosine kinase in megakaryocytes upon stem cell factor and phorbol myristate acetate stimulation and its association with paxillin. J Biol Chem (1997) 1.05
Monoclonal antibody against the centrosome. J Cell Sci (1989) 1.05
RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes. J Exp Med (1997) 1.04
Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.04